Monoclonal antibodies to programmed death 1 (PD-1)

Patent Number: 9387247

Patent Date: 2016-07-12

Patent type: utility

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.

Inventors

First Name Last Name City State Country
Mark J. Selby - - -
Alan J. Korman - - -
Mohan Srinivasan - - -
Haichun Huang - - -
Josephine M. Cardarelli - - -
Changyu Wang - - -
Bingliang Chen - - -

IPCs

Section Class Sub Class Group Sub Group
C 07 K 16 28
A 61 K 39 395
C 07 K 16 18
A 61 K 47 48
C 07 K 16 46
A 61 K 51 10
A 61 K 39 00

Assignee

Organization First Name Last Name City State Country
E. R. Squibb & Sons, Inc. - - - - -
Ono Pharmaceutical Co., Ltd. - - - - -